Pharma News
29 Jun 2025 to 05 Jul 2025
Jul 1, 2025
On the 1st, Samsung Bioepis revealed its plans to introduce "Obodence," a new therapy for ...
Samsung Bioepis, in collaboration with Hanmi Pharmaceutical, has launched "Obodens," a biosimilar for Amgen's osteoporosis drug Prolia, priced 13% lower at 108,290 won. Obodens, approved by the FDA and EC, offers advantages like easier storage and reduced pain from a thinner needle. The drug aims to provide a competitive treatment option for postmenopausal osteoporosis patients in Korea.
Jun 30, 2025
Novo Reaches $32 Million Settlement to Resolve Ozempic-Related Legal Dispute
Novo Nordisk AS and a group of insurers will pay $32 million to settle litigation regarding its $1.8 billion acquisition of Emisphere Technologies, which is linked to the oral version of the diabetes drug Ozempic. The settlement addresses claims against Lionsgate chairman Mark Rachesky for exploiting his control over Emisphere. Court approval is required for the agreement.
Jun 30, 2025
Chinese-developed obesity medications may drive the next generation of therapies - Nature
Chinese pharmaceutical companies are advancing next-generation obesity drugs, notably ecnoglutide, a GLP-1 receptor agonist that led to significant weight loss in a phase III trial. Funded by Sciwind Biosciences, ecnoglutide showed participants losing up to 13.8 kg. Additionally, mazdutide, developed by Eli Lilly and manufactured by Innovent Biologics, is also in trials, promising tailored treatments for obesity and related conditions.
Jun 30, 2025
China introduces its inaugural weight loss medication as the emerging market is set for swift expansion.
Eli Lilly & Co's Zepbound and Novo Nordisk's Wegovy face competition in China from Innovent Biologics' newly approved weight-loss drug, mazdutide. With over 600 million Chinese adults projected to be overweight by 2050, the local market for obesity treatments is expected to grow significantly, potentially reaching up to $11.4 billion annually.
Jun 30, 2025
Are Indian Firms Capable of Competing with Multinational Corporations in GLP-1 Manufacturing? - BioSpectrum India
As patents for blockbuster GLP-1 drugs like Semaglutide expire in India by 2026, Indian pharmaceutical companies are poised to launch generics, potentially transforming the diabetes and obesity treatment landscape. Companies such as Biocon, Sun Pharma, and Dr. Reddy’s are preparing to capitalize on this opportunity, while challenges like regulatory hurdles and manufacturing complexities remain.
